Search Results 601-610 of 18048 for Alopecia

1. A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC - Mayo Clinic

   Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy (excluding alopecia). Participants with ≥grade 2 pneumonitis from prior ...

2. Geographic tongue - Symptoms and causes - Mayo Clinic

   Geographic tongue may look alarming, but it does not cause health issues. Sometimes it can cause tongue pain and make you more sensitive to certain foods.

3. A Phase Ⅲ Study Of Rilvegostomig In Combination With Fluoropyrimidine And Trastuzumab Deruxtecan As The First-line Treatment For HER2-positive Gastric Cancer - Mayo Clinic

   Persistent toxicities caused by previous anti-cancer therapy excluding alopecia, not yet improved to Grade ≤ 1 or baseline. Note: Participants may be ...

4. A Study to Evaluate Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma - Mayo Clinic

   ... alopecia. Patients who have endocrinopathies associated with prior immunotherapy treatment but which are controlled with replacement therapy are eligible ...

5. Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma - Mayo Clinic

   Patients should have resolution of any toxic effects of prior therapy (except alopecia) to National Cancer Institute (NCI) Common Terminology Criteria for ...

6. Low-Dose or High-Dose Lenalidomide in Treating Children with Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma - Mayo Clinic

   ... alopecia, weight changes and grade I or II lymphopenia. Myelosuppressive chemotherapy: must not have received within 3 weeks of entry onto this study (6 ...

7. Ingrown hair - Symptoms and causes - Mayo Clinic

   Learn about causes, treatment and prevention of this common, painful skin condition — sometimes called razor bumps, barber's itch, shave bumps and ...

8. A Study to Evaluate Trabectedin with Olaparib in Advanced Unresectable or Metastatic Sarcoma - Mayo Clinic

   Persistent toxicities (>Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia. Patients with ...

9. Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC) - Mayo Clinic

   Participants with type 1 diabetes, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible; ...

10. A Study to Evaluate Belinostat and Guadecitabine or ASTX727 to Treat Unresectable and Metastatic Conventional Chondrosarcoma - Mayo Clinic

    ... alopecia and endocrinopathies from prior immunotherapy-based treatments that are well-controlled with hormone replacement. Patients who are receiving any ...